Mutual of America Capital Management’s Regenxbio RGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-7,483
Closed -$198K 1555
2022
Q3
$198K Buy
7,483
+1,108
+17% +$32.9K ﹤0.01% 1366
2022
Q2
$157K Buy
6,375
+952
+18% +$23.8K ﹤0.01% 1397
2022
Q1
$180K Buy
5,423
+281
+5% +$7.81K ﹤0.01% 1379
2021
Q4
$168K Buy
5,142
+143
+3% +$4.87K ﹤0.01% 1399
2021
Q3
$210K Buy
4,999
+43
+0.9% +$1.55K ﹤0.01% 1338
2021
Q2
$193K Buy
4,956
+302
+6% +$10.8K ﹤0.01% 1400
2021
Q1
$159K Buy
4,654
+897
+24% +$38.3K ﹤0.01% 1427
2020
Q4
$170K Buy
3,757
+163
+5% +$5.7K ﹤0.01% 1335
2020
Q3
$99K Buy
3,594
+2,044
+132% +$66.6K ﹤0.01% 1403
2020
Q2
$57K Buy
1,550
+179
+13% +$6.67K ﹤0.01% 1307
2020
Q1
$44K Buy
1,371
+294
+27% +$12.2K ﹤0.01% 1317
2019
Q4
$44K Sell
1,077
-77
-7% -$3.04K ﹤0.01% 1383
2019
Q3
$41K Buy
1,154
+42
+4% +$1.7K ﹤0.01% 1389
2019
Q2
$57K Buy
1,112
+231
+26% +$11.5K ﹤0.01% 1306
2019
Q1
$50K Buy
881
+147
+20% +$7.28K ﹤0.01% 1284
2018
Q4
$31K Buy
734
+175
+31% +$10.3K ﹤0.01% 1360
2018
Q3
$42K Buy
559
+460
+465% +$33.1K ﹤0.01% 1282
2018
Q2
$7K Buy
+99
New +$4.73K ﹤0.01% 1312

Other funds holding RGNX

Mutual of America Capital Management's RGNX Position: Q4 2022 in Review

Mutual of America Capital Management sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 7,483 shares — an estimated $198K sold.

Mutual of America Capital Management first reported a position in RGNX in Q2 2018 and held it in 18 quarters. The position peaked at $210K in Q3 2021. 182 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

  • Mutual of America Capital Management reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
  • Mutual of America Capital Management sold 7,483 Regenxbio shares in Q4 2022, an estimated $198K.
  • Mutual of America Capital Management first reported a position in Regenxbio in Q2 2018 and held it in 18 quarters.
  • Mutual of America Capital Management's Regenxbio position peaked at $210K in Q3 2021.
  • 182 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on Mutual of America Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.